GRAND FORKS, N.D.--(BUSINESS WIRE)--The University of North Dakota (UND) and NeoMatrix, LLC announced today that they have signed an exclusive option agreement to develop an assay to aid in the early detection of breast cancer.
The HALO® breast test is cleared globally for physicians and is designed to help screen and assess breast cancer risk in women using cytology.
The HALO® breast test is cleared globally for physicians and is designed to help screen and assess breast cancer risk in women using cytology.
